A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia.

Trial Profile

A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs BL 1020 (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms CLARITY
  • Sponsors BioLineRx
  • Most Recent Events

    • 20 Mar 2013 Status changed from recruiting to discontinued, according to a BioLineRx media release.
    • 20 Mar 2013 Primary endpoint 'Cognitive-function' has not been met, according to a BioLineRx media release.
    • 04 Feb 2013 The interim analysis expected in March 2013 will be performed on 235 randomised patients from 27 sites in Romania and India according to a BioLineRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top